Affinity Asset Advisors, LLC has filed an amended Schedule 13G, revealing that it holds no shares of Forte Biosciences, Inc. This filing is significant as it highlights the company's current investment stance and may influence perceptions within the pharmaceutical preparations industry.

Affinity Asset Advisors, LLC, incorporated in Delaware, is a limited liability company that operates as an investment advisor. The firm is based in New York and focuses on managing investments for clients. The recent filing, dated November 13, 2026, is part of a series of amendments to its Schedule 13G, which tracks ownership stakes in publicly traded companies.

According to the filing, Affinity Asset Advisors and its managing member, Michael Cho, reported that they beneficially own zero shares of common stock of Forte Biosciences, Inc. As of September 30, 2026, the reporting persons have no voting or investment power over any shares of the issuer. The filing states, "As of September 30, 2026, the Reporting Persons beneficially own approximately 0.0% of the Common Stock outstanding." This lack of ownership may indicate a strategic shift or a reevaluation of their investment in Forte.

This update may affect various stakeholders, including investors and analysts monitoring both Affinity Asset Advisors and Forte Biosciences. It may also prompt competitors within the pharmaceutical preparations sector to reassess their own strategies in light of Affinity's current position.

Details were not available in the SEC filing regarding what actions, if any, will follow this update. The filing does not specify future intentions or plans related to Forte Biosciences or any other investments.